AI is transforming drug discovery and clinical trials, making what was once cutting-edge the new standard. Pharma companies are evolving into tech companies, leveraging AI to revolutionize every phase of drug development.
In this episode, Chris McSpiritt, VP of Life Sciences Strategy at Domino, discusses how AI is no longer a niche capability for select firms but an essential capability for all biopharma organizations. We explore AI-based digital organisms, the increasing reliance on AI in clinical trials, and the shift toward personalized medicine.
Join us as we dive into:
- How AI will drive the majority of new drug discoveries
- The role of AI in clinical trials
- The growing need for pharma companies to adopt a tech company mindset
- The impact of AI-driven automation on regulatory compliance and reporting
